Literature DB >> 16675347

Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation.

Aicha Saadane1, Jindrich Soltys, Melvin Berger.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is characterized by an excessive and prolonged inflammatory response to Pseudomonas aeruginosa in the lung. There are high levels of cytokines and chemokines and an exaggerated PMN influx causing significant morbidity and mortality.
OBJECTIVE: To compare the kinetics of the inflammatory response with the kinetics of clearance of acute bacterial challenge in the lungs of CF and wild-type (WT) mice.
METHODS: We challenged CF knockout (KO) and WT mice intratracheally with P aeruginosa in suspension and evaluated bacteria counts, nuclear factor-kappaB (NF-kappaB), and inhibitor of NF-kappaB alpha protein (I-kappaBalpha) in lung tissue, cytokines, and PMN in bronchoalveolar lavage (BAL).
RESULTS: Both groups of mice cleared the infection with the same kinetics. CF-KO mice had more PMN in BAL than WT mice. CF-KO mice had high concentrations of proinflammatory cytokines in BAL on days 2 and 4, whereas cytokines in BAL from WT mice were only slightly elevated. CF-KO mice failed to regenerate I-kappaBalpha once it was degraded, and consequently had prolonged and excessive activation of NF-kappaB for the entire 6-day duration of the study. In contrast, WT mice showed only slight NF-kappaB activation, which plateaued at day 4.
CONCLUSION: These data suggest that NF-kappaB is dysregulated in CF lung infection and could be a good target for therapy. Prolonged responses to initial acute infections may contribute to the eventual establishment of chronic persistent inflammation. CLINICAL IMPLICATIONS: Dysregulation of the I-kappaB/NF-kappaB pathway in cystic fibrosis leads to prolonged cytokine secretion and persistent inflammation in response to acute challenges and may be important in the development of chronic lung inflammation and infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675347     DOI: 10.1016/j.jaci.2006.01.052

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  Proteases, cystic fibrosis and the epithelial sodium channel (ENaC).

Authors:  P H Thibodeau; M B Butterworth
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

2.  Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.

Authors:  Aicha Saadane; Sophia Masters; Joseph DiDonato; Jingfeng Li; Melvin Berger
Journal:  Am J Respir Cell Mol Biol       Date:  2007-02-01       Impact factor: 6.914

3.  Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.

Authors:  Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

4.  Alveolar inflammation in cystic fibrosis.

Authors:  Martina Ulrich; Dieter Worlitzsch; Simona Viglio; Nanna Siegmann; Paolo Iadarola; Janis K Shute; Marianne Geiser; Gerald B Pier; Godehard Friedel; Mark L Barr; Antje Schuster; Keith C Meyer; Felix Ratjen; Thomas Bjarnsholt; Erich Gulbins; Gerd Döring
Journal:  J Cyst Fibros       Date:  2010-03-29       Impact factor: 5.482

5.  Peroxiredoxin 6 fails to limit phospholipid peroxidation in lung from Cftr-knockout mice subjected to oxidative challenge.

Authors:  Stéphanie Trudel; Mairead Kelly; Janine Fritsch; Thao Nguyen-Khoa; Patrice Thérond; Martine Couturier; Michal Dadlez; Janusz Debski; Lhousseine Touqui; Benoit Vallée; Mario Ollero; Aleksander Edelman; Franck Brouillard
Journal:  PLoS One       Date:  2009-06-29       Impact factor: 3.240

Review 6.  Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling.

Authors:  David Nichols; James Chmiel; Melvin Berger
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 7.  Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.

Authors:  Xiaoqing Guan; Yuning Hou; Fei Sun; Zhe Yang; Chunying Li
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

8.  Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium.

Authors:  Aura Perez; Anna M van Heeckeren; David Nichols; Sanhita Gupta; Jean F Eastman; Pamela B Davis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-06-13       Impact factor: 5.464

9.  Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice.

Authors:  Yufa Wang; Elvis Cela; Stéphane Gagnon; Neil B Sweezey
Journal:  Respir Res       Date:  2010-11-30

10.  Expression of PPARγ and paraoxonase 2 correlated with Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Phoebe E Griffin; Louise F Roddam; Yvonne C Belessis; Roxanne Strachan; Sean Beggs; Adam Jaffe; Margaret A Cooley
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.